title: Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
authors.affiliation: Department of Hematology, University Hospital Dubrava, Avenija Gojka Suska 6, 10000, Zagreb, Croatia.
authors.forename: Marko
authors.initials: M
authors.lastname: Lucijanic
authors.forename: Ruzica
authors.initials: R
authors.lastname: Lasan-Trcic
authors.forename: Rajko
authors.initials: R
authors.lastname: Kusec
authors.forename: Vlatko
authors.initials: V
authors.lastname: Pejsa
authors.forename: Tajana
authors.initials: T
authors.lastname: Stoos-Veic
authors.forename: Ozren
authors.initials: O
authors.lastname: Jaksic
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002872:Chromosome Deletion; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics*; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D014178:Translocation, Genetic
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine